Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Dipeptidyl peptidase IV (DPP-IV, CD26) is frequently dysregulated in cancer and plays an important role in regulating multiple bioactive peptides with the potential to influence cancer progression and the recruitment of immune cells. Therefore, it represents a potential contributing factor to cancer...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/9/2072 |
| _version_ | 1797505469281992704 |
|---|---|
| author | Petr Busek Jonathan S. Duke-Cohan Aleksi Sedo |
| author_facet | Petr Busek Jonathan S. Duke-Cohan Aleksi Sedo |
| author_sort | Petr Busek |
| collection | DOAJ |
| description | Dipeptidyl peptidase IV (DPP-IV, CD26) is frequently dysregulated in cancer and plays an important role in regulating multiple bioactive peptides with the potential to influence cancer progression and the recruitment of immune cells. Therefore, it represents a potential contributing factor to cancer pathogenesis and an attractive therapeutic target. Specific DPP-IV inhibitors (gliptins) are currently used in patients with type 2 diabetes mellitus to promote insulin secretion by prolonging the activity of the incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Nevertheless, the modulation of the bioavailability and function of other DPP-IV substrates, including chemokines, raises the possibility that the use of these orally administered drugs with favorable side-effect profiles might be extended beyond the treatment of hyperglycemia. In this review, we critically examine the possible utilization of DPP-IV inhibition in cancer prevention and various aspects of cancer treatment and discuss the potential perils associated with the inhibition of DPP-IV in cancer. The current literature is summarized regarding the possible chemopreventive and cytotoxic effects of gliptins and their potential utility in modulating the anti-tumor immune response, enhancing hematopoietic stem cell transplantation, preventing acute graft-versus-host disease, and alleviating the side-effects of conventional anti-tumor treatments. |
| first_indexed | 2024-03-10T04:19:02Z |
| format | Article |
| id | doaj.art-82783598598444559294809af6df6c1b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T04:19:02Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-82783598598444559294809af6df6c1b2023-11-23T07:54:27ZengMDPI AGCancers2072-66942022-04-01149207210.3390/cancers14092072Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?Petr Busek0Jonathan S. Duke-Cohan1Aleksi Sedo2Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech RepublicDepartment of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USALaboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech RepublicDipeptidyl peptidase IV (DPP-IV, CD26) is frequently dysregulated in cancer and plays an important role in regulating multiple bioactive peptides with the potential to influence cancer progression and the recruitment of immune cells. Therefore, it represents a potential contributing factor to cancer pathogenesis and an attractive therapeutic target. Specific DPP-IV inhibitors (gliptins) are currently used in patients with type 2 diabetes mellitus to promote insulin secretion by prolonging the activity of the incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Nevertheless, the modulation of the bioavailability and function of other DPP-IV substrates, including chemokines, raises the possibility that the use of these orally administered drugs with favorable side-effect profiles might be extended beyond the treatment of hyperglycemia. In this review, we critically examine the possible utilization of DPP-IV inhibition in cancer prevention and various aspects of cancer treatment and discuss the potential perils associated with the inhibition of DPP-IV in cancer. The current literature is summarized regarding the possible chemopreventive and cytotoxic effects of gliptins and their potential utility in modulating the anti-tumor immune response, enhancing hematopoietic stem cell transplantation, preventing acute graft-versus-host disease, and alleviating the side-effects of conventional anti-tumor treatments.https://www.mdpi.com/2072-6694/14/9/2072gliptincancertumor microenvironmentimmune responsechemokinestromal cell-derived factor |
| spellingShingle | Petr Busek Jonathan S. Duke-Cohan Aleksi Sedo Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease? Cancers gliptin cancer tumor microenvironment immune response chemokine stromal cell-derived factor |
| title | Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease? |
| title_full | Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease? |
| title_fullStr | Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease? |
| title_full_unstemmed | Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease? |
| title_short | Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease? |
| title_sort | does dpp iv inhibition offer new avenues for therapeutic intervention in malignant disease |
| topic | gliptin cancer tumor microenvironment immune response chemokine stromal cell-derived factor |
| url | https://www.mdpi.com/2072-6694/14/9/2072 |
| work_keys_str_mv | AT petrbusek doesdppivinhibitionoffernewavenuesfortherapeuticinterventioninmalignantdisease AT jonathansdukecohan doesdppivinhibitionoffernewavenuesfortherapeuticinterventioninmalignantdisease AT aleksisedo doesdppivinhibitionoffernewavenuesfortherapeuticinterventioninmalignantdisease |